ArticleWorld journal of surgical oncology2025
Comprehensive genomic landscape of metastatic hormone-sensitive prostate cancer in the Chinese population.
Article in World journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Polygenic risk and germline genetics for prostate cancer in Asians: Where do we stand?Investigative and clinical urology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundProstate cancer is the most common cancer in urology. While the genomic profiles and prognostic biomarkers of metastatic castration-resistant prostate cancer (mCRPC) have been well studied, the genomic characteristics of Chinese metastatic hormone-sensitive prostate cancer (mHSPC) and their association with clinical features remain incompletely characterized. This study aimed to characterize the genomic landscape of mHSPC in a Chinese cohort and explore correlations with clinical characteristics, with comparisons to data from the Stand Up to Cancer-Prostate Cancer Foundation (SU2C-PCF) cohort.
methodsIn this retrospective study, 52 patients diagnosed with mHSPC were enrolled, and tumor samples were subjected to targeted sequencing. Clinical, demographic, and pathological data were collected. The association between genomic alterations and clinical features was analyzed using Pearson's chi-squared test tests. Comparative analysis was performed using the SU2C-PCF cohort.
resultsCompared to the SU2C-PCF cohort, Chinese patients with mHSPC had significantly higher mutation frequencies in FOXA1 (36.54% vs. 12.0%, P < 0.001), KDM6A (15.4% vs. 4.0%, P < 0.01), PIK3CA (15.4% vs. 4.7%, P = 0.01), and CTNNB1 (11.5% vs. 4.0%, P = 0.047), while AR mutations were significantly more frequent in the SU2C-PCF cohort (1.9% vs. 22.7%, P < 0.001). Homologous recombination repair gene mutations were detected in 36.54% of patients. PIK3CA mutations were associated with low PSA levels (50% vs. 11%, P = 0.044), TP53 mutations were significantly enriched in patients with high Gleason scores (43% vs. 0%, P < 0.001), and KDM6A (7% vs. 30%, P = 0.046) and SPOP (3% vs. 30%, P = 0.012) mutations were significantly enriched in patients with low Gleason scores.
conclusionsChinese patients with mHSPC have a distinct genomic landscape and show high genomic heterogeneity, TP53 mutation was significantly enriched in patients with mHSPC with high Gleason scores.
trial registrationNot applicable. This study is a retrospective observational analysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.